CD19/CD22/CD3 (CC) can eliminate B-ALL cells in vivo. (A) Schematic representation showing the experimental design. NCG mice (n = 5/group) were IV implanted with Nalm6 cells stably transduced with firefly luciferase at 0.5 × 106 cells per mouse on study day 0. Five days after tumor implantation, the mice were IV administered 30 × 106 expanded T cells and then intraperitoneally administered bsAbs, bsAbs in combination, or CD19/CD22/CD3 (CC) at 5.33 nmol/kg daily for 7 consecutive days. Similar results were obtained in 2 independent experiments. (B) Representative bioluminescence images of mice treated with bsAbs or tsAb. Colors indicate the intensity of luminescence (red, highest; blue, lowest). (C) Average radiance quantification (p/s/cm2/sr) of the luminescence is shown. Statistical significance was calculated using the Dunnett multiple comparisons test. ∗∗∗P < .001. (D) Survival curves of mice treated with bsAbs or tsAb. The log-rank (Mantel‒Cox) test was used to calculate significance. ∗∗∗P < .001. (E) Serum cytokines were evaluated by enzyme-linked immunosorbent assay (ELISA) 2 hours after the first drug infusion on day 6. Data are plotted as the mean ± SD. ∗P < .01, ∗∗P < .05, ∗∗∗P < .001.
